Supply Chain Considerations for an Early-stage Portfolio

Alex Haag | SVP, Global Development  CMC Biologicals, Boehringer Ingelheim

ADC Global Filing Strategy

Baolin Zhang | Global Chief Regulatory Officer, Qilu Pharmaceutical

Multi-payload ADCs: Therapeutic Promise and Manufacturing Challenge

Morris Rosenberg | CEO, MRBC Consulting

Safety Challenges in Next-Generation Conjugate Therapeutics: Bispecific and Dual-Payload ADCs, Antibody–Oligonucleotide Conjugates, and Peptide–Drug Conjugates

Rakesh Dixit | CEO&President, Bionavigen Oncology

Targeting Tumour-Specific Glycans with High-Affinity Antibodies

Jean Engela | CEO, Tacalyx

Keys to Raising Capital for Early Stage Companies

Rick Heinick | CEO and Chairman, SLAM BioTherapeutics

Building with the Buyer in Mind: The CrossBridge Journey from Lab to Eli Lilly

Michael Torres | Co-Founder & CSO, Artan Bio

Novel Payload for Antibody Drug Conjugate

Xavier Preville | CSO, Adcytherix Sas

Development of a Novel ADC Targeting B7-H7

Jamie Strand | Vice President, Technical Operations, NextPoint Therapeutics

Expanding Payload Diversity in Next-Generation ADCs through IntoCell’s OHPAS™ Linker and PMT™ Technologies

Hyun Young KOO | Head of BD, IntoCell

The Incorporation of AI/Machine Learning in ADC Development

Dowdy Jackson | CSO, Antigenix Therapeutics

XDC Late-Stage Development: Bridging to Commercial Success

Yuhua Hu | Head of US and EU CMC, WuXi XDC

Key Elements of Isolator CCS from Design to Qualification: VPHP Function Development and Validation

Wenlei Wu | General Manager, Tofflon

Strategic Payload-Linker CMC: Enabling Late-Stage ADC Development, PPQ Readiness and Commercial Success

Jack Yang | Senior Director of XDC Payload Linker Chemistry, WuXi XDC

Preclinical Safety and Efficacy QP101: A Novel HER2-targeting Dual Payload ADC Combining Topoisomerase I (TOP1) and Cyclin Dependent Kinase 7 (CDK7) Inhibitors

Kiyean Nam | CSO&CEO, Qurient

Preclinical Development of ABL209/NEOK002, an EGFRxMUC1 Bispecific ADC

Jinwon Jung | Senior Director, ABL Bio

Advanced Tool Enzyme of WuXi Bio: Empowering Conjugation Biologics

Sam Zhang | Vice President, Head of Microbial&Viral Platforms, WuXi Biologics

ADC Resistance Platform and Pharmacology Evaluation The Next Generation of ADC Development

Xiaohe Shi | Senior Principle Scientist II, WuXi AppTec

Novel ADC Payloads Designed to Target RNA Splicing to Drive Differentiated Efficacy and Safety and New options for ADC Therapy Sequencing

Abizer Gaslightwala | President and Chief Executive Officer, Akari Therapeutics

Accelerating Next-Generation Targeted Conjugates: Integrated Discovery Solutions for Dual-Payload ADCs, AOCs, and APCs

Gang Yin | VP, Head of Discovery Service, WuXi XDC 

Building the Next Generation of ADCs: Novel Payloads and Dual-Payload Platforms

Soo Min Lee | CSO, Samjin Pharm

Discovery and Development of Antiviral Fc Conjugate Drugs for Influenza Prophylaxis

Jim Wu | CEO, Shanghai Ark Biopharmaceutical